查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456941

生育力测试市场－2024年至2029年预测

Fertility Test Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

不孕症检测市场预计将从2022年的531,831,000美元增加到2029年的775,732,000美元，复合年增长率为5.54%。

不孕症检测市场受到多种因素的影响，包括人们对不孕症问题的认识提高和检测技术的进步。持续的技术改进正在提高这些测试的准确性、易用性和可访问性，从而提高普及率。此外，人们越来越重视预防性医疗保健，增加了对不孕症检测的需求，将其视为管理整体生殖健康和及早发现潜在问题的主动手段。

市场区隔包括排卵预测套件、生育力监测仪、男性不孕测试和其他选择。排卵预测套件迎合寻求自然受孕的女性，并提供多种选择，包括尿液检查、唾液测试和数位监测器。生育力监测仪提供先进的功能，如周期追踪和个人化见解。

男性不孕症检测套组可用于家庭使用和临床使用，并评估活力、浓度和型态等因素。其他选择包括荷尔蒙检测套组、卵巢储备检测套组和基因检测套组。

从市场区隔来看，市场分为女性不孕检测与男性不孕检测。女性不孕症检测包括针对月经和荷尔蒙水平不同方面的各种检测，反映了女性不孕症的盛行率较高。相反，男性不孕测试显示人们对预防医学的兴趣日益浓厚，从而导致了用户友好的家庭检测套组的开发。

根据最终用户细分，市场分为居家照护机构和医院/生育诊所。排卵预测套件和基本精液分析套件等非处方笺(OTC) 测试主要用于居家医疗环境。相较之下，医院和生育诊所提供全面的生育测试，包括处方笺荷尔蒙评估和专业诊断评估。

儘管面临人口结构变化和医疗保健环境等挑战，但市场格局仍有望显着成长。透过解决这些趋势和障碍，不孕症检测使个人和夫妇能够就其生殖健康和计划生育目标做出明智的决定。

市场驱动因素：

  • 传播人们对不孕症的认识的努力正在推动市场的成长。

由于不孕症旅游和首次怀孕的增加，不孕症检测市场预计将持续成长。此外，关于不孕症意识和早期检测的有利倡议和宣传活动，加上女性中 PCOD（卵巢卵巢病）患病率的增加，进一步支持了市场扩张。

用于医疗咨询的远距远端医疗服务的日益普及也是不孕症检测市场的主要驱动力。远端医疗为个人提供了一个方便易用的平台，可以远距接受不孕症检查并咨询专家，促进早期疗育和个人化指导。

  • 首次生育年龄增加的趋势

越来越多的女性出于各种原因推迟抚养孩子，包括追求高等教育、发展职业生涯和获得财务稳定。与低度开发国家，此一趋势在已开发国家尤为明显，首次当妈妈的平均年龄在美国为27岁，在英国为29岁，在乌干达为19.4岁，被认为是首次当妈妈的平均年龄。根据中央情报局的资料，开发中国家正在变得越来越贵。

随着女性推迟组建家庭，不孕症检测对于发现可能影响怀孕和婴儿健康的问题变得越来越重要。早期早期疗育和介入可以改善妊娠结局，降低与高风险妊娠相关的风险，并有助于降低婴幼儿死亡率。

不孕症检测 ING 在识别可能影响怀孕和婴幼儿健康的潜在问题方面发挥着重要作用。及时介入和治疗这些问题可以改善妊娠结局，降低与高风险妊娠相关的风险，并最终有助于降低婴儿死亡率 (IMR)。例如，2020年的IMR为29，2021年下降至28。

市场限制因素：

  • 成本限制

检测可能是一项财务挑战，因为它通常包括不孕不育检测、专家咨询和必要的后续调查的费用。这项费用可能会阻碍夫妻接受检查，尤其是对于保险不涵盖生育相关服务的夫妇。

虽然一些保险计划部分或全部承保不孕不育检查，但许多保险计划不包括此类承保或对有资格报销的检查类型施加限制。可能存在这种情况。缺乏财政支持是人们寻求不孕症检查的主要障碍。

根据购买型态，不孕症检测市场分为处方笺和非处方笺类。

依购买型态细分不孕检测市场，分为处方笺类和非处方笺类。已被诊断出患有不孕症或具有复杂医学背景的人可以在医疗专业人员的指导和解释下处方笺不孕症检测。

相反，非处方笺(OTC) 不孕症测试适合有不孕症健康问题但未诊断出问题的个人，并且与处方笺测试相比，提供了更经济的选择。

北美预计将占据不孕不育检测市场的巨大份额

北美地区，尤其是美国，不孕率相对较高，受延迟生育、环境因素和生活方式选择等因素影响。这种高盛行率强调了早期诊断和及时介入的重要性，推动了对不孕症检测解决方案的需求增加。

在北美，男性和女性都越来越意识到自己的生育测试选择和好处。教育宣传活动、媒体报导和不孕症相关问题的公开讨论正在促进这种认识的提高。因此，对于寻求积极主动的方法来解决不孕问题的个人来说，对不孕症检测服务的需求不断增长。

公司产品

  • Geratherm Medical AG - Geratherm Medical AG 是不孕不育检测解决方案的先驱供应商之一，其主要产品「Basal」和「Early Detect」提供有关生育和早期检测的资讯。产品「Geratherm Early Detect」可在几分钟内提供结果，并支持早期检测现有怀孕。
  • Fairhaven Health - Fairhaven Health 提供由医生设计的怀孕、不孕和哺乳产品，包括排卵预测器。
  • Mankind Pharma Ltd - Mankind Pharma Ltd 的不孕症和怀孕测试解决方案易于使用，范围涵盖从怀孕前到怀孕后。 PrgaNews品牌的产品提供排卵和怀孕（之前和之后）测试解决方案，包括排卵计算器和怀孕预产期计算器。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章不孕症检测市场：依产品

  • 介绍
  • 排卵产品套件
    • 市场趋势和机会
    • 成长前景
  • 生育力监测仪
    • 市场趋势和机会
    • 成长前景
  • 男性生育能力检测套组
    • 市场趋势和机会
    • 成长前景
  • 其他的
    • 市场趋势和机会
    • 成长前景

第六章不孕症检测市场：依应用分类

  • 介绍
  • 女性用生育力测试
    • 市场趋势和机会
    • 成长前景
  • 男性生育能力测试
    • 市场趋势和机会
    • 成长前景

第七章 生育力测试市场：按购买方式

  • 介绍
  • 基于处方笺
    • 市场趋势和机会
    • 成长前景
  • 非处方笺依据
    • 市场趋势和机会
    • 成长前景

第八章不孕症检测市场：依最终用户分类

  • 介绍
  • 居家照护环境
    • 市场趋势和机会
    • 成长前景
  • 医院和生育诊所
    • 市场趋势和机会
    • 成长前景

第九章不孕不育检测市场：依地区

  • 介绍
  • 北美洲
    • 副产品
    • 按用途
    • 按购买方式
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 副产品
    • 按用途
    • 按购买方式
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 副产品
    • 按用途
    • 按购买方式
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 副产品
    • 按用途
    • 按购买方式
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 副产品
    • 按用途
    • 按购买方式
    • 按最终用户
    • 按国家/地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • Church & Dwight Co., Inc.
  • Geratherm Medical AG
  • Fertility Focus
  • Fairhaven Health LLC
  • bioZhena Corporation
  • Hilin Life Products, Inc.
  • UEBE Medical GmbH
  • AdvaCare Pharma
  • Mankind Pharma Ltd.
  • Modern Fertility
简介目录
Product Code: KSI061611911

The fertility test market is projected to rise at a compound annual growth rate (CAGR) of 5.54% to reach a market valuation of US$775.732 million by 2029, from US$531.831 million in 2022.

The fertility test market is subject to various influences, including heightened awareness of fertility issues and advancements in testing technology. Ongoing technological enhancements are improving the accuracy, ease of use, and accessibility of these tests, driving their adoption rates. Additionally, a growing emphasis on preventive healthcare is fueling demand for fertility testing as a proactive means of managing overall reproductive health and detecting potential issues early on.

In terms of product segmentation, the fertility test market encompasses ovulation product kits, fertility monitors, men's fertility testing kits, and other options. Ovulation predictor kits cater to women seeking natural conception, offering a range of choices such as urine tests, saliva tests, and digital monitors. Fertility monitors provide advanced features like cycle tracking and personalized insights.

Male fertility testing kits, available for home and clinical use, assess factors like motility, concentration, and morphology. Other options include hormone testing kits, ovarian reserve tests, and genetic testing kits.

In terms of application segmentation, the market is divided into female fertility testing and male fertility testing. Female fertility testing comprises various tests tailored to different aspects of the menstrual cycle and hormonal levels, reflecting the higher prevalence of female infertility concerns. Conversely, male fertility testing demonstrates an increasing focus on preventive healthcare, leading to the development of user-friendly home-based testing kits.

End-user segmentation categorizes the market into homecare settings and hospitals/fertility clinics. Homecare settings primarily feature non-prescription (OTC) tests such as ovulation predictor kits and basic semen analysis kits. In contrast, hospitals and fertility clinics offer a comprehensive range of fertility tests, including prescription-based hormonal assessments and specialized diagnostic evaluations.

Despite challenges like shifting demographics and healthcare landscapes, the fertility test market is poised for significant growth. By addressing these trends and obstacles, fertility testing empowers individuals and couples to make informed decisions about their reproductive health and family planning goals.

Market Drivers:

  • Initiatives to spread infertility awareness have bolstered the market growth.

The fertility test market is anticipated to grow at a constant rate, which is attributable to the growing fertility tourism and first-time pregnancies. In addition, favorable initiatives and campaigns regarding infertility awareness and early detection, coupled with the growing prevalence of PCOD (Polycystic Ovary Disease) among females, have further bolstered the market expansion.

The rising popularity of telehealth services for healthcare consultations is also significantly driving the fertility test market. Telehealth provides a convenient and accessible platform for individuals to undergo remote fertility testing and consult with specialists, facilitating early intervention and personalized guidance.

  • Trend towards a rising age of first-time mothers

Women are increasingly postponing parenthood for a variety of reasons, including pursuing higher education, advancing their careers, or attaining financial stability. This trend is particularly prominent in developed nations compared to underdeveloped ones, with the average age of first-time mothers being higher in countries such as the US (27 years), the UK (29 years), and Uganda (19.4 years), which is considered a developing country according to CIA data.

As women delay starting families, fertility testing becomes increasingly crucial in identifying potential issues that could impact pregnancy and infant health. Early detection and intervention can lead to improved pregnancy outcomes, reduce the risks associated with high-risk pregnancies, and contribute to a decline in the infant mortality rate.

Fertility testing plays a critical role in identifying potential issues that may affect both pregnancy and infant health. Timely intervention and treatment for these concerns can enhance pregnancy outcomes, mitigate risks associated with high-risk pregnancies, and ultimately contribute to reducing the infant mortality rate (IMR). For example, while the IMR was 29 in 2020, it decreased to 28 by 2021.

Market Restraint:

  • Cost-related restraints

Fertility testing procedures can pose a financial challenge, as they often include costs associated with the tests, consultations with specialists, and any necessary follow-up investigations. This expense can dissuade certain couples from pursuing testing, particularly those without insurance coverage for fertility-related services.

Although some insurance plans provide partial or complete coverage for fertility testing, many plans do not include such coverage or may impose restrictions on the types of tests eligible for reimbursement. The absence of financial assistance can be a notable obstacle for individuals seeking fertility testing.

The fertility test market is segmented by mode of purchase into prescription-based and non-prescription-based categories.

The segmentation of the fertility test market by mode of purchase divides it into prescription-based and non-prescription-based categories. Prescription-based Fertility Tests cater to individuals facing diagnosed fertility issues or possessing complex medical backgrounds, with the involvement of medical professionals offering guidance and interpretation.

Conversely, non-prescription (OTC) fertility tests are suitable for individuals with fertility health concerns but without diagnosed problems, offering a more economical option compared to prescription-based tests.

North America is anticipated to hold a significant share of the fertility test market

In North America, notably in the United States, infertility rates are relatively high, influenced by factors such as delayed childbearing, environmental factors, and lifestyle choices. This heightened prevalence underscores the importance of early diagnosis and timely intervention, driving the increasing demand for fertility testing solutions.

Both men and women in North America are becoming increasingly aware of the available fertility testing options and their associated benefits. This growing awareness is fueled by educational campaigns, media coverage, and open discussions about fertility-related issues. Consequently, there is a rising demand for fertility testing services as individuals seek proactive approaches to addressing fertility concerns.

Company Products:

  • Geratherm Medical AG - Geratherm Medical AG is one of the pioneering providers of fertility testing solutions whose major offerings, namely "Basal" & "Early Detect", assist in providing information about possible pregnancies and early detection. Product: "Geratherm Early Detect" provides results within a few minutes and assists in detecting existing pregnancies at an early stage.
  • Fairhaven Health - Fairhaven Health offers doctor-designed pregnancy, fertility & nursing products inclusive of ovulation predictors. Product: "BFP Early Ovulation Test Strips" are eco-friendly, and affordable and predict ovulation by detecting LH surge.
  • Mankind Pharma Ltd - Mankind Pharma Ltd's fertility and pregnancy testing solutions are easy to use and range from pre-pregnancy to post-pregnancy offerings. Product: The PrgaNews brand provides ovulation and pregnancy (pre- & post-) testing solutions, including an ovulation calculator and a pregnancy due date calculator.

Market Segmentation:

By Product

  • Ovulation Product Kits
  • Fertility Monitors
  • Men's Fertility Testing Kits
  • Others

By Application

  • Female Fertility Testing
  • Male Fertility Testing

By Mode of Purchase

  • Prescription based
  • Non-prescription based

By End-User

  • Homecare setting
  • Hospitals and Fertility Clinics

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. FERTILITY TEST MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Ovulation Product Kits
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
  • 5.3. Fertility Monitors
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
  • 5.4. Men's Fertility Testing Kits
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
  • 5.5. Others
    • 5.5.1. Market Trends and Opportunities
    • 5.5.2. Growth Prospects

6. FERTILITY TEST MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Female Fertility Testing
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
  • 6.3. Male Fertility Testing
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects

7. FERTILITY TEST MARKET BY MODE OF PURCHASE

  • 7.1. Introduction
  • 7.2. Prescription based
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
  • 7.3. Non-prescription based
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects

8. FERTILITY TEST MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Homecare setting
    • 8.2.1. Market Trends and Opportunities
    • 8.2.2. Growth Prospects
  • 8.3. Hospitals and Fertility Clinics
    • 8.3.1. Market Trends and Opportunities
    • 8.3.2. Growth Prospects

9. FERTILITY TEST MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Mode Of Purchase
    • 9.2.4. By End-user
    • 9.2.5. By Country
      • 9.2.5.1. United States
        • 9.2.5.1.1. Market Trends and Opportunities
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Trends and Opportunities
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Trends and Opportunities
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Application
    • 9.3.3. By Mode Of Purchase
    • 9.3.4. By End-user
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Trends and Opportunities
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Trends and Opportunities
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Trends and Opportunities
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Application
    • 9.4.3. By Mode Of Purchase
    • 9.4.4. By End-user
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Trends and Opportunities
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Trends and Opportunities
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Trends and Opportunities
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Others
        • 9.4.5.4.1. Market Trends and Opportunities
        • 9.4.5.4.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Application
    • 9.5.3. By Mode Of Purchase
    • 9.5.4. By End-user
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Trends and Opportunities
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Trends and Opportunities
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Israel
        • 9.5.5.3.1. Market Trends and Opportunities
        • 9.5.5.3.2. Growth Prospects
      • 9.5.5.4. South Africa
        • 9.5.5.4.1. Market Trends and Opportunities
        • 9.5.5.4.2. Growth Prospects
      • 9.5.5.5. Others
        • 9.5.5.5.1. Market Trends and Opportunities
        • 9.5.5.5.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Application
    • 9.6.3. By Mode Of Purchase
    • 9.6.4. By End-user
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Trends and Opportunities
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. Japan
        • 9.6.5.2.1. Market Trends and Opportunities
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Trends and Opportunities
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Trends and Opportunities
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Trends and Opportunities
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Australia
        • 9.6.5.6.1. Market Trends and Opportunities
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Others
        • 9.6.5.7.1. Market Trends and Opportunities
        • 9.6.5.7.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisition, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Church & Dwight Co., Inc.
  • 11.2. Geratherm Medical AG
  • 11.3. Fertility Focus
  • 11.4. Fairhaven Health LLC
  • 11.5. bioZhena Corporation
  • 11.6. Hilin Life Products, Inc.
  • 11.7. UEBE Medical GmbH
  • 11.8. AdvaCare Pharma
  • 11.9. Mankind Pharma Ltd.
  • 11.10. Modern Fertility